No­var­tis and Bio­gen pull out of neu­ro drug part­ner­ships with Sang­amo

Sang­amo lost two big-name part­ners in the span of a few days, af­ter No­var­tis and Bio­gen pulled out of their part­ner­ships with the biotech com­pa­ny.

Bio­gen signed up in Feb­ru­ary 2020 to part­ner up with Sang­amo on the search for new gene reg­u­la­tion ther­a­pies to treat neu­ro­log­i­cal dis­or­ders, pay­ing $350 mil­lion up­front plus an eq­ui­ty in­vest­ment for ac­cess to Sang­amo’s zinc fin­ger pro­teins. The No­var­tis col­lab­o­ra­tion, with a $75 mil­lion up­front, fol­lowed a few months lat­er, sim­i­lar­ly fo­cused on neu­rode­vel­op­men­tal dis­or­ders.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.